Grifols begins European launch of XEMBIFY in Spain to treat

Barcelona, Spain - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines, has started marketing XEMBIFY®, its 20% subcutaneous immunoglobulin, in Spain. This plasma medicine is indicated for treating primary immunodeficiencie...

Related Keywords

Spain , United Kingdom , Australia , Montserrat , Barcelona , Comunidad Autonoma De Cataluna , United States , Spanish , Guillain Barre , Joana Sabat , Wa Carrock Sewell , Research Bureau , Nasdaq , European Union , Hematology Group , Senior Vice President , Biopharma Launch , Expanding Field , Secondary Antibody Deficiency , Practice Guidelines , Report Analysis , Global Usage , Immunoglobulin Market , Signal Onco Hematology , Secondary Immunodeficiency Diseases , Warning Signs ,